ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 751

Pregnancy Outcome in Patients with Takayasu Arteritis: The Results of Turkish Takayasu Study Group

Nilufer Alpay-Kanitez 1, Sema Kaymaz-Tahra 2, Ayten Yazici 3, Ayse Cefle 4, Mete Kara 5, Handan Yarkan-Tugsal 6, Onay Gercik 7, Servet Akar 8, Fatos Onen 9, Kenan Aksu 10, Gokhan Keser 5, Cemal Bes 11, Sevil Kamalı 12, Fatma Alibaz-Oner 13 and Haner Direskeneli14, 1Koc University School of Medicine, Division of Rheumatology, İstanbul, Turkey, 2Marmara University School of Medicine, Division of Rheumatology, Istanbul, Istanbul, Turkey, 3Kocaeli University, Faculty of Medicine, Division of Rheumatology, Kocaeli, Kocaeli, Turkey, 4Kocaeli University, Faculty of Medicine, Division of Rheumatology, Kocaeli, Turkey, 5Ege University School of Medicine, Division of Rheumatology, Izmir, Turkey, 6Dokuz Eylul University School of Medicine, Division of Rheumatology, Izmir, Turkey, 7Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, Izmir, Turkey, 8Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, 9Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey, 10Ege University, Department of Internal Medicine, Division of Rheumatology, Izmir, 11University of Medical Sciences, İstanbul, Turkey, 12Private office, İstanbul, Turkey, 13Marmara University Faculty of Medicine,Department of Rheumatology,Istanbul,Turkey, Istanbul, Turkey, 14Marmara University, School of Medicine, Division of Rheumatology, Istanbul, Turkey

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: takayasu arteritis and pregnancy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Takayasu's Arteritis & Polymyalgia Rheumatica

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Takayasu’s arteritis (TAK) is a large vessel vasculitis of the young women in their reproductive age. According to our previous report from single center TAK pregnancies may have a favorable outcome. On the other hand, pregnancy outcomes were worse in the French TAK cohort. Herein, we reported fetal and maternal complications of pregnancy in a larger group of Turkish TAK patients.

Methods: A total of 68 TAK patients, followed by Turkish Takayasu Study Group in 7 tertiary centers and diagnosed according to the 1990 ACR criteria were consecutively assessed for pregnancy and newborn outcome. Pregnancies were divided into 2 groups as pre-diagnosis (pre-d) and post-diagnosis (post-d) pregnancies and compared to fetomaternal complications (FMC) such as hypertension (HT), preeclampsia-eclampsia, abortion, prematurity, low birth weight. Post-d pregnancies were also divided into 2 groups according to FMC development status and baseline demographic data and TAK clinical characteristics were compared between groups.

Results: The mean age of the patients who received 167 pregnancy data retrospectively was 43±12.1 years. 42 (25.1%) of these pregnancies developed after the onset of the disease. FMC rate was higher in the post-d pregnancies than in the pre-d pregnancies [15 (35.7%), 20 (15.7%); p = 0.006]. FMC are shown in Table 1. Maternal heart failure, cardiovascular event or death was not observed in any pregnancy. Disease characteristics of patients with post-d pregnancies according to FMC development are seen in Table 2. None of the patients was smoker and had cardiovascular events.

Table 1: Fetomaternal complications in pre-d and post-d pregnancies (IUGR: Intrauterine growth retardation)

Pre-d pregnancies

n: 127 (%)

Post-d pregnancies

n: 40 (%)

 

p

Maternal complications

Hypertension-new

0

2 (5)

0.061

Hypertension-worsening

0

8 (20)

0.000

Preeclampsia/eclampsia

0

1 (2.5)

0.249

Fetal complications

Abortion

13 (10.2)

4 (10)

0.616

Prematurity

2 (1.5)

2 (5)

0.258

Low birth weight

2 (1.5)

2 (5)

0.153

IUGR

1 (0.7)

0

0.751

Fetal anomaly

0

1 (2.5)

0.249

Fetal death

2 (1.5)

0

0.564

Tablo 2: Disease characteristics of patients with post-d pregnancies according to FMC development (SS: Standard deviation)

FMC +, n:15 (%)

FMC -, n:27 (%)

p

Age (Mean±SD)

27.1±4.5

26.7±4.7

0.695

Hypertension

4 (26.6)

11 (40.7)

0.285

Cardiac valvular disease

3 (20)

10 (37)

0.215

Cerebrovascular event

1 (6.6)

2 (7.4)

0.713

Renal artery involvement

9 (60)

8 (29.6)

0.056

Conclusion: The most common maternal complications of TAK patients are associated with HT. It was observed that TAK negatively affected the fetal outcomes of pregnancies however the majority of the pregnancies were found as successful in our cohort.


Disclosure: N. Alpay-Kanitez, None; S. Kaymaz-Tahra, None; A. Yazici, None; A. Cefle, None; M. Kara, None; H. Yarkan-Tugsal, None; O. Gercik, None; S. Akar, Abbvie, 2, 5, Amgen, 2, 5, MSD, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, 8, Roche, 2, 5, UCB, 2, 5; F. Onen, Tofacitinib (Pfizer), 8; K. Aksu, None; G. Keser, None; C. Bes, None; S. Kamalı, None; F. Alibaz-Oner, None; H. Direskeneli, None.

To cite this abstract in AMA style:

Alpay-Kanitez N, Kaymaz-Tahra S, Yazici A, Cefle A, Kara M, Yarkan-Tugsal H, Gercik O, Akar S, Onen F, Aksu K, Keser G, Bes C, Kamalı S, Alibaz-Oner F, Direskeneli H. Pregnancy Outcome in Patients with Takayasu Arteritis: The Results of Turkish Takayasu Study Group [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/pregnancy-outcome-in-patients-with-takayasu-arteritis-the-results-of-turkish-takayasu-study-group/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pregnancy-outcome-in-patients-with-takayasu-arteritis-the-results-of-turkish-takayasu-study-group/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology